Clinical Trial

Bipolar Androgen Therapy + Carboplatin in mCRPC

Study acronym: HiTeCH
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to determine the efficacy of BAT and carboplatin in men with metastatic castrate-resistant prostate cancer (mCRPC).
Protocol Amendment History 11 amendments
This ClinicalTrials.gov record has been amended 11 times since 2018-05-10; most recent amendment 2026-04-22.
Status change: Not Yet Recruiting → Recruiting 2018-08-02
Trial Details
NCT Number NCT03522064
Lead Sponsor St Vincent's Hospital, Sydney
Conditions Castration-resistant Prostate Cancer, Homologous Recombination Deficiency
Enrollment 30 participants
Start Date 2018-07-30
Primary Completion 2026-09-30 (estimated)
Study Completion 2027-12-30 (estimated)
Updated on ClinicalTrials.gov 2026-04-23